Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM
Glioblastoma multiforme (GBM) remains a cancer with a poor prognosis and few effective therapeutic options. Successful medical management of GBM is limited by the restricted access of drugs to the central nervous system (CNS) caused by the blood brain barrier (BBB). We previously showed that a subse...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Publishing Group
2018
|
| Subjects: |
| _version_ | 1797091148430311424 |
|---|---|
| author | Przystal, J Hajji, N Khozoie, C Renziehausen, A Zeng, Q Abaitua, F Hajitou, A Suwan, K Want, E Bomalaski, J Szlosarek, P O'Neill, K Crook, T Syed, N |
| author_facet | Przystal, J Hajji, N Khozoie, C Renziehausen, A Zeng, Q Abaitua, F Hajitou, A Suwan, K Want, E Bomalaski, J Szlosarek, P O'Neill, K Crook, T Syed, N |
| author_sort | Przystal, J |
| collection | OXFORD |
| description | Glioblastoma multiforme (GBM) remains a cancer with a poor prognosis and few effective therapeutic options. Successful medical management of GBM is limited by the restricted access of drugs to the central nervous system (CNS) caused by the blood brain barrier (BBB). We previously showed that a subset of GBM are arginine auxotrophic because of transcriptional silencing of ASS1 and/or ASL and are sensitive to pegylated arginine deiminase (ADI-PEG20). However, it is unknown whether depletion of arginine in peripheral blood in vivo has therapeutic activity against intracranial disease. In the present work, we describe the efficacy of ADI-PEG20 in an intracranial model of human GBM in which tumour growth and regression are assessed in real time by measurement of luciferase activity. Animals bearing intracranial human GBM tumours of varying ASS status were treated with ADI-PEG20 alone or in combination with temozolomide and monitored for tumour growth and regression. Monotherapy ADI-PEG20 significantly reduces the intracranial growth of ASS1 negative GBM and extends survival of mice carrying ASS1 negative GBM without obvious toxicity. The combination of ADI-PEG20 with temozolomide (TMZ) demonstrates enhanced effects in both ASS1 negative and ASS1 positive backgrounds.Our data provide proof of principle for a therapeutic strategy for GBM using peripheral blood arginine depletion that does not require BBB passage of drug and is well tolerated. The ability of ADI-PEG20 to cytoreduce GBM and enhance the effects of temozolomide argues strongly for its early clinical evaluation in the treatment of GBM. |
| first_indexed | 2024-03-07T03:28:52Z |
| format | Journal article |
| id | oxford-uuid:b9ffe66a-dbec-4317-8100-bcdbef1b70e3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:28:52Z |
| publishDate | 2018 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:b9ffe66a-dbec-4317-8100-bcdbef1b70e32022-03-27T05:07:05ZEfficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBMJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b9ffe66a-dbec-4317-8100-bcdbef1b70e3*subject*EnglishSymplectic Elements at OxfordNature Publishing Group2018Przystal, JHajji, NKhozoie, CRenziehausen, AZeng, QAbaitua, FHajitou, ASuwan, KWant, EBomalaski, JSzlosarek, PO'Neill, KCrook, TSyed, NGlioblastoma multiforme (GBM) remains a cancer with a poor prognosis and few effective therapeutic options. Successful medical management of GBM is limited by the restricted access of drugs to the central nervous system (CNS) caused by the blood brain barrier (BBB). We previously showed that a subset of GBM are arginine auxotrophic because of transcriptional silencing of ASS1 and/or ASL and are sensitive to pegylated arginine deiminase (ADI-PEG20). However, it is unknown whether depletion of arginine in peripheral blood in vivo has therapeutic activity against intracranial disease. In the present work, we describe the efficacy of ADI-PEG20 in an intracranial model of human GBM in which tumour growth and regression are assessed in real time by measurement of luciferase activity. Animals bearing intracranial human GBM tumours of varying ASS status were treated with ADI-PEG20 alone or in combination with temozolomide and monitored for tumour growth and regression. Monotherapy ADI-PEG20 significantly reduces the intracranial growth of ASS1 negative GBM and extends survival of mice carrying ASS1 negative GBM without obvious toxicity. The combination of ADI-PEG20 with temozolomide (TMZ) demonstrates enhanced effects in both ASS1 negative and ASS1 positive backgrounds.Our data provide proof of principle for a therapeutic strategy for GBM using peripheral blood arginine depletion that does not require BBB passage of drug and is well tolerated. The ability of ADI-PEG20 to cytoreduce GBM and enhance the effects of temozolomide argues strongly for its early clinical evaluation in the treatment of GBM. |
| spellingShingle | *subject* Przystal, J Hajji, N Khozoie, C Renziehausen, A Zeng, Q Abaitua, F Hajitou, A Suwan, K Want, E Bomalaski, J Szlosarek, P O'Neill, K Crook, T Syed, N Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM |
| title | Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM |
| title_full | Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM |
| title_fullStr | Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM |
| title_full_unstemmed | Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM |
| title_short | Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM |
| title_sort | efficacy of arginine depletion by adi peg20 in an intracranial model of gbm |
| topic | *subject* |
| work_keys_str_mv | AT przystalj efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT hajjin efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT khozoiec efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT renziehausena efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT zengq efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT abaituaf efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT hajitoua efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT suwank efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT wante efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT bomalaskij efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT szlosarekp efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT oneillk efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT crookt efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm AT syedn efficacyofargininedepletionbyadipeg20inanintracranialmodelofgbm |